1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Gastrointestinal Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Counter Declines from Patent Expiries

Gastrointestinal Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Counter Declines from Patent Expiries

Summary

GBI Research, the leading business intelligence provider, has released its latest research, ‘Gastrointestinal Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Counter Declines from Patent Expiries’, which provides insights into three gastrointestinal therapeutic indications in the major developed markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an in-depth analysis of three gastrointestinal therapeutics markets, namely Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC) and Crohn’s Disease (CD). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these three gastrointestinal indications.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis carried out by GBI Research’s team of industry experts.

In 2012, the value of the gastrointestinal therapeutics market in major developed countries amounted to an estimated $6.8 billion. This total is forecast to decline at a Compound Annual Growth Rate (CAGR) of 0.3% between 2012 and 2019. The value of the IBS market amounted to an estimated $727m, and is forecast to increase at a CAGR of 14.4% between 2012 and 2019. The value of the UC market amounted to an estimated $2.2 billion in 2012, and is expected to increase at a CAGR of 6% during the forecast period. The value of the CD market amounted to an estimated $3.8 billion, which is expected to decline at a CAGR of 7.5% between 2012 and 2019.

Scope

- The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals for the IBS, UC and CD indications in the major developed markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada.
- Disease overview and treatment usage patterns
- Market size and forecast for IBS, UC and CD in major developed markets from 2012 to 2019
- Major marketed products for the indication types covered
- In-depth pipeline analysis for IBS, UC and CD
- Key drivers and restraints that have had and are expected to have a major impact upon the market
- Key licensing and co-development agreements in the gastrointestinal therapeutics market

Reasons to buy

- Align your product portfolio to the markets with high growth potential
- Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments that are poised for strong growth
- Devise a more effectively tailored country-specific strategy through the understanding of key drivers and barriers in the gastrointestinal therapeutics market
- Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Table Of Contents

Gastrointestinal Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Counter Declines from Patent Expiries
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 10
2 Gastrointestinal Therapeutics in Major Developed Markets - Introduction 11
2.1 Irritable Bowel Syndrome 11
2.1.1 Classification 11
2.1.2 Symptoms 11
2.1.3 Etiology 11
2.1.4 Pathophysiology 12
2.1.5 Diagnosis 12
2.1.6 Epidemiology 13
2.1.7 Prognosis 14
2.1.8 Treatment Options 14
2.2 Ulcerative Colitis 15
2.2.1 Classification 15
2.2.2 Symptoms 16
2.2.3 Etiology 16
2.2.4 Pathophysiology 17
2.2.5 Diagnosis 17
2.2.6 Epidemiology 18
2.2.7 Prognosis 18
2.2.8 Treatment Options 19
2.3 Crohn's Disease 20
2.3.1 Classification 20
2.3.2 Symptoms 21
2.3.3 Etiology 21
2.3.4 Pathophysiology 22
2.3.5 Diagnosis 22
2.3.6 Epidemiology 23
2.3.7 Prognosis 23
2.3.8 Treatment Options 24
3 Gastrointestinal Therapeutics in Major Developed Markets - Marketed Products (Global) 25
3.1 Irritable Bowel Syndrome 25
3.2 Ulcerative Colitis 25
3.3 Crohn's Disease 25
3.4 Key Marketed Products 26
3.4.1 Amitiza 26
3.4.2 Humira 27
3.4.3 Remicade 28
3.4.4 Simponi 29
3.4.5 Cimzia 30
3.4.6 Tysabri 31
4 Gastrointestinal Therapeutics in Major Developed Markets - Pipeline Analysis 33
4.1 Irritable Bowel Syndrome 33
4.1.1 Overall Pipeline 33
4.1.2 Pipeline Analysis by Molecule Type 35
4.1.3 Pipeline Analysis by Mechanism of Action 36
4.2 Ulcerative Colitis Pipeline 38
4.2.1 Overall Pipeline 38
4.2.2 Pipeline Analysis by Molecule Type 40
4.2.3 Pipeline Analysis by Mechanism of Action 41
4.3 Crohn's Disease Pipeline 43
4.3.1 Overall Pipeline 43
4.3.2 Pipeline Analysis by Molecule Type 45
4.3.3 Pipeline Analysis by Mechanism of Action 46
4.4 Promising Drug Candidates in the Pipeline 48
4.4.1 GSK-1605786 48
4.4.2 MLN0002 48
4.4.3 EMD-61753 48
5 Gastrointestinal Therapeutics in Major Developed Markets - Market Forecast to 2019 49
5.1 Major Developed Markets 49
5.1.1 Treatment Usage Patterns 49
5.1.2 Annual Cost of Therapy 49
5.1.3 Market Size 49
5.2 US 51
5.2.1 Treatment Usage Patterns 51
5.2.2 Annual Cost of Therapy 51
5.2.3 Market Size 51
5.3 Europe 53
5.3.1 Treatment Usage Patterns 53
5.3.2 Annual Cost of Therapy 53
5.3.3 Market Size 53
5.4 Canada 55
5.4.1 Treatment Usage Patterns 55
5.4.2 Annual Cost of Therapy 55
5.4.3 Market Size 55
5.5 Japan 57
5.5.1 Treatment Usage Patterns 57
5.5.2 Annual Cost of Therapy 57
5.5.3 Market Size 57
5.6 Drivers and Barriers 59
5.6.1 Drivers 59
5.6.2 Barriers 59
6 Gastrointestinal Therapeutics in Major Developed Markets - Deals and Strategic Consolidations (Global) 61
6.1 Deals Analysis 61
6.2 Major Co-Development Deals 63
6.2.1 AstraZeneca Enters into Co-Development Agreement with Ironwood Pharma for Linaclotide 64
6.2.2 Amgen Enters into Co-development Agreement with AstraZeneca for Five Monoclonal Antibodies 64
6.2.3 Galapagos and AbbVie Extend GLPG0634 Development Agreement to Include Crohn's Disease 64
6.3 Major Licensing Deals 65
6.3.1 AstraZeneca Enters into Licensing Agreement with Ardelyx for NHE3 Inhibitor Program 66
6.3.2 Sanofi-Aventis Enters into Licensing Agreement with Kyowa Hakko Kirin 66
6.3.3 GlaxoSmithKline Enters into Licensing Agreement with ChemoCentryx 66
7 Gastrointestinal Therapeutics in Major Developed Markets - Appendix 67
7.1 All Pipeline Drugs by Phase 67
7.1.1 Discovery 67
7.1.2 Preclinical 67
7.1.3 IND/CTA-filed 68
7.1.4 Phase I 69
7.1.5 Phase II 70
7.1.6 Phase III 72
7.1.7 Pre-Registration 72
7.1.8 Undisclosed 73
7.2 Market Forecasts to 2019 73
7.2.1 Major Developed Markets 73
7.2.2 US 74
7.2.3 Canada 75
7.2.4 UK 76
7.2.5 France 77
7.2.6 Germany 78
7.2.7 Italy 79
7.2.8 Spain 80
7.2.9 Japan 81
7.3 Market Definitions 82
7.4 Abbreviations 82
7.5 Sources 84
7.6 Research Methodology 86
7.6.1 Coverage 86
7.6.2 Secondary Research 86
7.6.3 Primary Research 87
7.6.4 Therapeutic Landscape 87
7.6.5 Geographical Landscape 90
7.6.6 Pipeline Analysis 90
7.7 Expert Panel Validation 90
7.8 Contact Us 90
7.9 Disclaimer 901.1 List of Tables
Table 1: Gastrointestinal Therapeutics Market, Irritable Bowel Syndrome, Classification, 2009 11
Table 2: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Recommendations for Irritable Bowel Syndrome, 2009 15
Table 3: Gastrointestinal Therapeutics Market, Major Developed Markets, Classification of Ulcerative Colitis, 2004 15
Table 4: Gastrointestinal Therapeutics Market, Major Developed Markets, Diagnosis of Ulcerative Colitis, 2007 17
Table 5: Gastrointestinal Therapeutics Market, Major Developed Markets, Difference Between Ulcerative Colitis and Crohn's Disease, 2007 18
Table 6: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Options of Ulcerative Colitis, 2011 20
Table 7: Gastrointestinal Therapeutics Market, Major Developed Markets, Classification of Crohn's Disease, 2013 20
Table 8: Gastrointestinal Therapeutics Market, Major Developed Markets, Symptoms of Crohn's Disease, 2012 21
Table 9: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Options for Crohn's Disease , 2009 24
Table 10: Gastrointestinal Therapeutics Market, Global, Pipeline (Discovery), 2013 67
Table 11: Gastrointestinal Therapeutics Market, Global, Pipeline (Preclinical), 2013 67
Table 12: Gastrointestinal Therapeutics Market, Global, Pipeline (IND/CTA-filed), 2013 68
Table 13: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase I), 2013 69
Table 14: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase II), 2013 70
Table 15: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase III), 2013 72
Table 16: Gastrointestinal Therapeutics Market, Global, Pipeline (Pre-Registration), 2013 72
Table 17: Gastrointestinal Therapeutics Market, Global, Pipeline (Undisclosed), 2012 73
Table 18: Gastrointestinal Therapeutics Major Developed Markets, Irritable Bowel Syndrome, Market Forecast, 2012-2019 73
Table 19: Gastrointestinal Therapeutics Market, Major Developed Markets, Ulcerative Colitis, Market Forecast, 2012-2019 74
Table 20: Gastrointestinal Therapeutics Market, Major Developed Markets, Crohn's Disease, Market Forecast, 2012-2019 74
Table 21: Gastrointestinal Therapeutics Market, US, Irritable Bowel Syndrome, Market Forecast, 2012-2019 74
Table 22: Gastrointestinal Therapeutics Market, US, Ulcerative Colitis, Market Forecast, 2012-2019 75
Table 23: Gastrointestinal Therapeutics Market, US, Crohn's Disease, Market Forecast, 2012-2019 75
Table 24: Gastrointestinal Therapeutics Market, Canada, Irritable Bowel Syndrome, Market Forecast, 2012-2019 75
Table 25: Gastrointestinal Therapeutics Market, Canada, Ulcerative Colitis, Market Forecast, 2012-2019 76
Table 26: Gastrointestinal Therapeutics Market, Canada, Crohn's Disease, Market Forecast, 2012-2019 76
Table 27: Gastrointestinal Therapeutics Market, UK, Irritable Bowel Syndrome, Market Forecast, 2012-2019 76
Table 28: Gastrointestinal Therapeutics Market, UK, Ulcerative Colitis, Market Forecast, 2012-2019 77
Table 29: Gastrointestinal Therapeutics Market, UK, Crohn's Disease, Market Forecast, 2012-2019 77
Table 30: Gastrointestinal Therapeutics Market, France, Irritable Bowel Syndrome, Market Forecast, 2012-2019 77
Table 31: Gastrointestinal Therapeutics Market, France, Ulcerative Colitis, Market Forecast, 2012-2019 78
Table 32: Gastrointestinal Therapeutics Market, France, Crohn's Disease, Market Forecast, 2012-2019 78
Table 33: Gastrointestinal Therapeutics Market, Germany, Irritable Bowel Syndrome, Market Forecast, 2012-2019 78
Table 34: Gastrointestinal Therapeutics Market, Germany, Ulcerative Colitis, Market Forecast, 2012-2019 79
Table 35: Gastrointestinal Therapeutics Market, Germany, Crohn's Disease, Market Forecast, 2012-2019 79
Table 36: Gastrointestinal Therapeutics Market, Italy, Irritable Bowel Syndrome, Market Forecast, 2012-2019 79
Table 37: Gastrointestinal Therapeutics Market, Italy, Ulcerative Colitis, Market Forecast, 2012-2019 80
Table 38: Gastrointestinal Therapeutics Market, Italy, Crohn's Disease, Market Forecast, 2012-2019 80
Table 39: Gastrointestinal Therapeutics Market, Spain, Irritable Bowel Syndrome, Market Forecast, 2012-2019 80
Table 40: Gastrointestinal Therapeutics Market, Spain, Ulcerative Colitis, Market Forecast, 2012-2019 81
Table 41: Gastrointestinal Therapeutics Market, Spain, Crohn's Disease, Market Forecast, 2012-2019 81
Table 42: Gastrointestinal Therapeutics Market, Japan, Irritable Bowel Syndrome, Market Forecast, 2012-2019 81
Table 43: Gastrointestinal Therapeutics Market, Japan, Ulcerative Colitis, Market Forecast, 2012-2019 82
Table 44: Gastrointestinal Therapeutics Market, Japan, Crohn's Disease, Market Forecast, 2012-2019 821.2 List of Figures
Figure 1: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Algorithm of Ulcerative Colitis, 2007 19
Figure 2: Gastrointestinal Therapeutics Market, Global, Sales of Amitiza ($m), 2006-2012 26
Figure 3: Gastrointestinal Therapeutics Market, Global, Sales of Humira ($bn), 2006-2012 27
Figure 4: Gastrointestinal Therapeutics Market, Global, Sales of Remicade ($bn), 2006-2012 28
Figure 5: Gastrointestinal Therapeutics Market, Global, Sales of Simponi ($m), 2009-2012 29
Figure 6: Gastrointestinal Therapeutics Market, Global, Sales of Cimzia ($m), 2008-2012 30
Figure 7: Gastrointestinal Therapeutics Market, Global, Sales of Tysabri ($m), 2006-2012 31
Figure 8: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline, 2013 34
Figure 9: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline by Molecule Type, 2013 35
Figure 10: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline by Mechanism of Action, 2012 37
Figure 11: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline, 2013 39
Figure 12: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline by Molecule Type, 2013 40
Figure 13: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline by Mechanism of Action, 2013 42
Figure 14: Gastrointestinal Therapeutics Market, Global, Crohn's Disease, Pipeline, 2013 44
Figure 15: Gastrointestinal Therapeutics Market, Global, Crohn's Disease, Pipeline by Molecule Type, 2013 45
Figure 16: Gastrointestinal Therapeutics Market, Global, Crohn's Disease, Pipeline by Mechanism of Action, 2013 47
Figure 17: Gastrointestinal Therapeutics Market, Major Developed Markets, Market Size ($bn), 2012-2019 50
Figure 18: Gastrointestinal Therapeutics Market, US, Market Size ($bn), 2012-2019 52
Figure 19: Gastrointestinal Therapeutics Market, Top Five European Countries, Market Size ($bn), 2012-2019 54
Figure 20: Gastrointestinal Therapeutics Market, Canada, Market Size ($m), 2012-2019 56
Figure 21: Gastrointestinal Therapeutics Market, Japan, Market Size ($m), 2012-2019 58
Figure 22: Gastrointestinal Therapeutics Market, Global, Deals, 2006-2013 62
Figure 23: Gastrointestinal Therapeutics Market, Global, Co-Development Deals, 2006-2013 63
Figure 24: Gastrointestinal Therapeutics Market, Global, Licensing Deals, 2006-2013 65
Figure 25: GBI Research Market Forecasting Model 89

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.